Ureteral Stents Market Size & Forecasts 2026-2035, By Segments (Product Type, Application, Material, End-use), Growth Opportunities, Innovation Landscape, Regulatory Shifts, Strategic Regional Insights (U.S., Japan, China, South Korea, UK, Germany, France), and Competitive Dynamics (Boston Scientific, Cook Medical, B. Braun, Coloplast, Olympus)

Market Outlook

Ureteral Stents Market size is forecast to climb from USD 521.79 million in 2025 to USD 943.3 million by 2035, expanding at a CAGR of over 6.1% during 2026-2035. Industry revenue in 2026 is projected at USD 549.5 million.

• Base Year Value (2025): USD 521.79 Million
• CAGR (2026-2035): 6.1%
• Forecast Year Value (2035): USD 943.3 Million
• Historical Data Period: 2021-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Key Takeaways

• North America region dominated around 43.3% market share in 2025, driven by advanced healthcare systems.
• Asia Pacific region will expand at over 7% CAGR between 2026 and 2035, led by increasing urological procedures.
• The market share of hospitals segment stood at 68.6% in 2025, propelled by primary setting for urological surgeries.
• With a share of 49.5% in 2025, double pigtail segment’s dominance was secured by standard choice for urological procedures.
• Achieving 41.2% ureteral stents market share in 2025, the growth of kidney stones segment was underpinned by high prevalence of kidney stone cases globally.
• Leading organizations shaping the ureteral stents market include Boston Scientific (US), Cook Medical (US), B. Braun (Germany), Coloplast (Denmark), Olympus (Japan), Teleflex (US), C.R. Bard (US), Allium Medical Solutions (Israel), Applied Medical (US), ROCAMED (France).

Market Dynamics

Rising Incidence of Kidney Disorders Requiring Stenting

The ureteral stents market is significantly influenced by the increasing prevalence of kidney disorders, particularly conditions such as ureteral obstruction and kidney stones that necessitate stenting procedures. According to the World Health Organization, the global incidence of kidney diseases has been steadily rising, driven by factors such as diabetes and hypertension. This trend not only heightens the demand for ureteral stents but also encourages healthcare providers to adopt more advanced stenting solutions. Established players in the market, such as Boston Scientific, are responding by enhancing their product offerings, while new entrants can capitalize on this growing need by developing innovative stenting solutions tailored to specific patient demographics. As healthcare systems adapt to this rising demand, opportunities for collaboration with medical institutions and research organizations are likely to expand, driving further innovation and market growth.

Technological Innovations in Ureteral Stent Materials and Coatings

Innovations in ureteral stent materials and coatings are reshaping the ureteral stents market, enhancing both the efficacy and safety of stenting procedures. Recent advancements, such as the development of biocompatible materials and drug-eluting coatings, have been shown to reduce complications associated with stent placement, as highlighted by studies published in the Journal of Urology. These innovations not only improve patient outcomes but also align with the increasing regulatory focus on patient safety and product performance. Established companies like Cook Medical are leveraging these technological advancements to differentiate their products, while new entrants can explore niche markets by developing specialized stents that cater to specific clinical needs. The ongoing evolution of materials science in urology presents a strategic opportunity for both existing players and new innovators to enhance their market positions and meet the demands of a more discerning healthcare landscape.

Increasing Adoption in Emerging Markets Due to Healthcare Infrastructure Growth

The ureteral stents market is experiencing a notable shift as healthcare infrastructure in emerging markets improves, leading to increased adoption of advanced medical technologies. Countries such as India and Brazil are investing heavily in healthcare facilities and training, which is driving the demand for ureteral stents as part of comprehensive urological care. The World Bank reports that investments in healthcare infrastructure are correlated with better health outcomes, creating a fertile environment for the introduction of innovative stenting solutions. Established players have the opportunity to expand their market presence through strategic partnerships and distribution agreements, while new entrants can find success by offering cost-effective solutions that meet the specific needs of these growing markets. As healthcare systems in these regions continue to evolve, the ureteral stents market is poised for significant growth, supported by a robust demand for improved patient care.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising incidence of kidney disorders requiring stenting	1.70%	Short term (≤ 2 yrs)	North America (spillover: Europe)	High	Fast
Technological innovations in ureteral stent materials and coatings	1.40%	Medium term (2–5 yrs)	Europe (spillover: Asia Pacific)	Medium	Moderate
Increasing adoption in emerging markets due to healthcare infrastructure growth	1.00%	Long term (5+ yrs)	Asia Pacific (spillover: Latin America)	Low	Moderate

Industry Restraints:

Regulatory Compliance Challenges

The ureteral stents market is significantly constrained by stringent regulatory compliance requirements, which can delay product development and market entry. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) impose rigorous testing and approval processes that ensure safety and efficacy, but these can lead to extended timelines for manufacturers. For instance, the FDA's premarket approval process can take several years, during which companies must navigate extensive documentation and clinical trial requirements. This not only increases operational costs but also creates uncertainty for investors and stakeholders, leading to hesitancy in funding new innovations. As noted by the European Medicines Agency (EMA), compliance with evolving regulations in different regions adds further complexity for global players, often resulting in fragmented market strategies that limit growth potential.

Supply Chain Disruptions

Supply chain vulnerabilities present another critical restraint impacting the ureteral stents market. The reliance on specialized materials and components, often sourced from a limited number of suppliers, exposes manufacturers to risks associated with geopolitical tensions and economic fluctuations. For example, disruptions caused by the COVID-19 pandemic highlighted significant dependencies in the supply chain, leading to delays in production and increased costs. According to a report by the Medical Device Manufacturers Association (MDMA), these challenges have forced companies to reconsider their sourcing strategies and invest in more resilient supply chains. Established firms may face difficulties in adapting to these changes, while new entrants struggle to gain traction in a market already burdened by logistical complexities. Looking ahead, the ongoing emphasis on supply chain resilience will likely shape strategic priorities, pushing companies to innovate not just in product design but also in operational frameworks.

Regional Forecast

North America Market Statistics:

North America captured over 43.3% of the global ureteral stents market in 2025, establishing itself as both the largest region. The dominance of this region is attributed to advanced healthcare systems that prioritize innovative medical technologies and patient-centric care. This emphasis on quality healthcare drives demand for ureteral stents, as healthcare providers seek effective solutions for urinary tract obstructions. Furthermore, the region's robust regulatory framework and investment in healthcare infrastructure have fostered a conducive environment for market expansion, as evidenced by the American Urological Association's initiatives promoting the adoption of advanced urological devices. As North America continues to evolve in its healthcare delivery models, significant opportunities emerge for stakeholders in the ureteral stents market.

The United States anchors the North American ureteral stents market, leveraging its advanced healthcare infrastructure and high consumer demand for innovative medical solutions. The U.S. market is characterized by a growing preference for minimally invasive procedures, which aligns with the increasing adoption of ureteral stents that enhance patient recovery times and reduce hospital stays. Regulatory bodies such as the Food and Drug Administration (FDA) play a critical role in ensuring the safety and efficacy of these devices, further encouraging innovation and competition among manufacturers. Notably, companies like Boston Scientific are actively expanding their product offerings to meet the evolving needs of healthcare providers, positioning themselves strategically within the market. The U.S. thus serves as a vital driver of growth in the regional ureteral stents market, presenting substantial opportunities for investment and development.

Asia Pacific Market Analysis:

The Asia Pacific region emerged as the fastest-growing market for ureteral stents, posting a robust CAGR of 7%. This growth is primarily driven by the increasing number of urological procedures, which has led to a heightened demand for effective and reliable stent solutions. The region's healthcare infrastructure is evolving rapidly, with investments in advanced medical technologies and surgical techniques becoming more prevalent. This shift not only enhances the quality of care but also aligns with the rising consumer preference for minimally invasive procedures, thereby propelling the ureteral stents market forward. Countries like Japan and China are at the forefront of this transformation, characterized by significant advancements in healthcare policies and practices that support urological health. Furthermore, the ongoing digital transformation in healthcare is streamlining operations, improving patient outcomes, and fostering innovation in stent design and functionality. As a result, the Asia Pacific region presents significant opportunities for stakeholders in the ureteral stents market, driven by a combination of technological advancements and evolving consumer demands.

Japan plays a critical role in the ureteral stents market, characterized by its advanced healthcare system and a high volume of urological procedures. The increasing adoption of minimally invasive techniques in Japanese hospitals reflects a shift in consumer demand towards safer and more efficient treatment options. Regulatory support from the Ministry of Health, Labour and Welfare has facilitated quicker approvals for innovative medical devices, enhancing market access for new ureteral stents. Moreover, Japanese manufacturers are investing in research and development to create stents that offer improved biocompatibility and patient comfort. For instance, recent collaborations between companies like Olympus Corporation and various healthcare institutions aim to develop next-generation stents tailored to specific patient needs. This strategic focus positions Japan as a key player in the regional ureteral stents market, reinforcing its significance in driving growth and innovation.

China, on the other hand, is witnessing a rapid expansion in its ureteral stents market, fueled by a surge in urological procedures and a growing aging population. The Chinese government's commitment to enhancing healthcare access through initiatives like the Healthy China 2030 plan has resulted in increased investments in medical infrastructure, including urology departments. Additionally, the rising prevalence of kidney stones and urinary tract disorders has prompted healthcare providers to adopt advanced stenting solutions. Companies such as Mindray Medical International have been pivotal in introducing high-quality ureteral stents that cater to the unique needs of the Chinese market. The competitive landscape is further intensified by local manufacturers striving to innovate and reduce costs, making ureteral stents more accessible to a broader patient base. This dynamic environment not only highlights China’s growing importance in the ureteral stents market but also underscores the region's overall potential for future growth.

Europe Market Trends:

The ureteral stents market in Europe held a commanding share, driven by a robust healthcare infrastructure and increasing prevalence of urinary tract disorders. This region is significant due to its advanced medical technology landscape, where innovative solutions are increasingly prioritized by healthcare providers. The demand for ureteral stents is bolstered by a growing aging population and a rising awareness of minimally invasive surgical options. Recent advancements in stent materials and designs, as noted by the European Association of Urology, have enhanced patient outcomes, reflecting a shift towards patient-centric care. Furthermore, regulatory frameworks across the European Union, particularly with the Medical Device Regulation (MDR), have encouraged manufacturers to improve product safety and efficacy, thereby enhancing market competitiveness. As Europe continues to invest in healthcare technologies and sustainability initiatives, the ureteral stents market is poised for significant opportunities in the coming years.

Germany plays a pivotal role in the ureteral stents market, characterized by its strong emphasis on research and development in medical devices. The country’s healthcare system is marked by high expenditure on advanced medical technologies, facilitating a favorable environment for the adoption of innovative ureteral stents. A report from the German Medical Technology Association highlights that local manufacturers are increasingly focusing on biocompatible materials, which cater to the growing consumer demand for safer and more effective solutions. Additionally, Germany's stringent regulatory environment ensures high standards, which not only boosts consumer confidence but also encourages international collaborations. This dynamic positions Germany as a leader in the European ureteral stents market, presenting strategic opportunities for investment and innovation.

France also holds a significant position in the ureteral stents market, driven by a supportive regulatory landscape and a strong emphasis on healthcare accessibility. The French healthcare system, known for its comprehensive coverage, has led to increased utilization of ureteral stents among patients requiring urological interventions. According to the French National Authority for Health, there has been a notable increase in the adoption of new stent technologies, particularly those that enhance patient comfort and reduce complications. Furthermore, France's commitment to digital health initiatives is fostering innovation in medical device management, allowing for better patient monitoring and outcomes. This environment not only enhances competition among manufacturers but also aligns with the broader regional trend of integrating technology into healthcare, thereby unlocking further growth potential in the ureteral stents market.

Regional Market Attractiveness & Strategic Fit Matrix
Parameter	North America	Asia Pacific	Europe	Latin America	MEA
Innovation Hub	Advanced	Developing	Advanced	Developing	Nascent
Cost-Sensitive Region	Low	Medium	Low	High	High
Regulatory Environment	Restrictive	Neutral	Restrictive	Neutral	Neutral
Demand Drivers	Strong	Moderate	Strong	Weak	Weak
Development Stage	Developed	Developing	Developed	Emerging	Emerging
Adoption Rate	High	Medium	High	Low	Low
New Entrants / Startups	Dense	Moderate	Dense	Sparse	Sparse
Macro Indicators	Strong	Strong	Stable	Stable	Weak

Segmentation Analysis

 

Analysis by End-use

The ureteral stents market is predominantly led by the hospitals segment, which captured over 68.6% share in 2025. This leadership is primarily attributed to hospitals being the primary setting for urological surgeries, where a significant volume of procedures necessitates the use of ureteral stents. As healthcare systems increasingly prioritize patient outcomes and operational efficiency, hospitals are investing in advanced urological technologies and training, enhancing procedural efficacy and patient care. These dynamics reflect a growing demand for reliable surgical solutions amidst evolving regulations from entities like the World Health Organization, which emphasize quality care. This segment creates strategic advantages for established firms, allowing them to expand their product offerings and for emerging players to innovate with tailored solutions. Given the ongoing advancements in surgical techniques and a sustained focus on urological health, the hospitals segment is expected to maintain its relevance in the near to medium term.

Analysis by Product Type

In the ureteral stents market, the double pigtail segment holds a commanding 49.5% share in 2025. Its prominence is largely due to being the standard choice for urological procedures, favored for its effectiveness in managing urinary obstructions. The preference for double pigtail stents aligns with trends toward minimally invasive techniques, as healthcare providers seek to enhance patient comfort and recovery times. Regulatory bodies like the U.S. Food and Drug Administration have also recognized the efficacy of these stents, further solidifying their market position. This segment offers established companies the opportunity to leverage their expertise while enabling new entrants to carve out niche markets through innovation. With continuous improvements in stent design and materials driven by technological advancements, the double pigtail segment is poised to remain a cornerstone of the ureteral stents market.

Analysis by Application

The ureteral stents market is significantly influenced by the kidney stones application segment, which represented more than 41.2% in 2025. This segment's dominance stems from the high prevalence of kidney stone cases globally, prompting healthcare providers to adopt effective management strategies. The growing awareness of kidney health and preventive measures is driving demand for stenting solutions, as patients increasingly seek timely interventions. Organizations such as the National Kidney Foundation highlight the importance of addressing kidney stone issues, which further emphasizes the necessity for effective treatment options. The kidney stones segment presents substantial opportunities for both established companies to enhance their product lines and emerging players to introduce innovative solutions tailored to patient needs. As the incidence of kidney stones continues to rise, the relevance of this segment in the ureteral stents market is expected to persist, supported by ongoing public health initiatives.

Report Segmentation
Segment	Sub-Segment
Product Type	Double pigtail, Open-ended, Close-ended, Multiloop
Application	Kidney stones, Kidney transplant, Urinary tract infection, Other applications
Material	Metal stents, Polyurethane stents, Silicon stents, Hydrogel stents
End-use	Hospitals, Ambulatory surgical centers, Other end-users

Competitive Landscape

Key players in the ureteral stents market include Boston Scientific, Cook Medical, B. Braun, Coloplast, Olympus, Teleflex, C.R. Bard, Allium Medical Solutions, Applied Medical, and ROCAMED. These companies are recognized for their innovative approaches and strong market presence, each contributing unique strengths to the sector. Boston Scientific and Cook Medical, for instance, leverage extensive research and development capabilities to enhance product offerings, while B. Braun and Coloplast emphasize high-quality manufacturing standards and patient-centric designs. Olympus and Teleflex are noted for their advanced technological integrations, which enhance procedural efficiencies, while C.R. Bard and Allium Medical Solutions focus on niche markets and tailored solutions that address specific clinical needs. Applied Medical and ROCAMED further diversify the competitive landscape through strategic product differentiation and targeted marketing efforts, solidifying their roles as influential players in the ureteral stents domain.

The competitive environment in the ureteral stents market is characterized by dynamic interactions among these leading companies, which are actively pursuing various strategic initiatives to enhance their market standing. Collaborative efforts between firms are increasingly common, with alliances formed to drive innovation and expand product lines. New product launches are frequently observed, showcasing advancements in material technology and design that improve patient outcomes. Additionally, investments in research and development are pivotal, as companies strive to integrate cutting-edge technologies that streamline procedures and improve the overall efficacy of ureteral stents. This proactive approach not only fosters competitiveness but also stimulates innovation, allowing these key players to maintain a robust presence in a rapidly evolving market landscape.

Strategic / Actionable Recommendations for Regional Players

In North America, market participants should consider forging partnerships with healthcare providers to enhance distribution channels and gain insights into emerging patient needs. Engaging in collaborative research initiatives with academic institutions could also facilitate the development of next-generation ureteral stents that incorporate advanced materials and technologies.

For players in the Asia Pacific region, tapping into the growing demand for minimally invasive procedures presents an opportunity for innovation. Focusing on the development of cost-effective solutions tailored to local market conditions can drive adoption, as can leveraging digital health technologies to improve patient monitoring and follow-up care.

In Europe, responding to regulatory changes and increasing emphasis on patient safety will be crucial. Companies may benefit from aligning their product development strategies with evolving healthcare policies and standards, while also exploring potential alliances with local distributors to enhance market penetration and brand visibility.

Competitive Dynamics and Strategic Insights
Assessment Parameter	Assigned Scale	Scale Justification
Market Concentration	High	Dominated by key players (e.g., Boston Scientific, Cook Medical) with strong brand presence.
Degree of Product Differentiation	High	Polymer and metallic stents offer unique comfort and durability.
Competitive Advantage Sustainability	Durable	Rising kidney stone prevalence and aging populations ensure demand.
Innovation Intensity	High	Advances in biocompatible and anti-encrustation stents drive R&D.
M&A Activity / Consolidation Trend	Active	Acquisitions (e.g., Boston Scientific’s 2024 urology deals) target advanced stent technologies.
Customer Loyalty / Stickiness	Strong	Clinicians rely on trusted brands for safety and efficacy, with high switching costs.
Vertical Integration Level	High	Major firms control R&D, manufacturing, and distribution for proprietary stent designs.